(+Video) But what did he say in Arabic?
...Gal-On and other Meretz MK’s did not ask Abbas to repeat that
policy statement on the “Voice of Palestine”‘ – the PBC Palestine
Broadcasting Corporation radio or TV network, in the Arabic language
David Bedein..
Times of Israel..
26 August '13..
On Thursday, August 22, 2013, Meretz members of Knesset met with Mahmoud
Abbas, whose term as the elected leader of the Palestinian Authority
finished three years ago.
In a statement broadcast on the 11 PM August 22 newsreel of the “Voice
of Israel” Israel Broadcasting Authority Radio, Meretz Knesset faction
leader Zahava Gal-On proudly presented Abbas’s policy statement
delivered to Meretz that he would relinquish the PLO vision of the
“right of return” to the areas lost in 1948- Tzfat, Jaffa, Acre,
BeerSheva, and more.
Gal-On and other Meretz MK’s did not ask Abbas to repeat that policy
statement on the “Voice of Palestine”‘ – the PBC Palestine Broadcasting
Corporation radio or TV network, in the Arabic language.
By
way of example what would be needed to be seen and heard would be the
opposite of the following 08 August broadcast, the actual constant of
what has been broadcast and promoted throughout the Abbas presidency
irrespective of talks, negotiations, or public statements to the
English-speaking press and audience. (Yosef)
Published on Aug 18, 2013
http://palwatch.org/main.aspx?fi=450&fld_id=450&doc_id=9568
Radio
announcer: "Greetings to all our listeners and happy holiday to you,
our people in occupied Palestine (i.e., Israel), 1948 Palestine, the
1948 territories (i.e., Israel, created in 1948)... Greetings to our
people in Acre, Nazareth, Tiberias, Haifa and Jaffa (all Israeli
cities)... May your Palestinian identity be rooted in your hearts and
minds. Allah willing, one day Palestine will be Palestine again!"
[Voice of Palestine (official PA radio), Aug. 8, 2013]
Meretz did not ask Abbas to order a change in the curriculum for the PA
and UNRWA school system, in the new school year, where the PA/UNRWA
school curriculum is based on the inculcation of the “Right of Return”
through the “armed struggle” to liberate Palestine, all of Palestine in
the hearts and minds of every Palestinian student.
To my colleagues in the media, the question remains, will reporters
challenge Gal-On about the questionable policy announcement issued by
Meretz following their meeting with Abbas.
Bottom line:
Abbas has facilitated a system which is preparing every nook and cranny
of Palestinian society for total war with Israel, to liberate all of
Palestine
Abbas all media outlets at his disposal to issue daily messages which encourage and endorse those who kill Jews.
This is not a right wing issue.
This is reality, ignored and played down by the Oslo process advocates for 20 years,
This is where a Erev Rosh HaShanah self-accountability process should come under consideration.
Abbas is a greater master of disinformation than Arafat, and is well
dressed and will always say the right thing in English for any group
that visits him, since he knows that his visitors will not ask the right
questions.
Original title: Meretz visit with Abbas : But what did he say in Arabic?
Link: http://blogs.timesofisrael.com/meretz-visit-with-abbas-but-what-did-he-say-in-arabic/
Updates throughout the day at http://calevbenyefuneh.blogspot.com. If you enjoy "Love of the Land", please be a subscriber. Just put your email address in the "Subscribe" box on the upper right-hand corner of the page.Twitter updates at LoveoftheLand as well as our Love of the Land page at Facebook which has additional pieces of interest besides that which is posted on the blog. Check-it out!
Januvia Lawsuits
What is Januvia?
Januvia (sitagliptin) was first approved in October 2006 by the U.S. Food and
Drug Administration (
FDA).
The drug was created in an effort to help patients previously diagnosed
with type 2 diabetes gain control of their blood glucose levels. The
first of its kind, the oral medication was classified as a DPP-4
inhibitor that helped to increase the body’s production of insulin.
Unfortunately, studies have shown that the drug may directly raise the
patient’s risk of developing pancreatitis and pancreatic cancer
following an initial dose and subsequent dosage increases. Patients
experiencing these side effects have filed Januvia lawsuits seeking
damages for their suffering.
History of Januvia
Januvia
was created by Merck & Co., Inc. to help the body produce insulin
by affecting the incretin system and targeting pancreatic cells, yet it
may also restrict the body from fighting against various types of
cancer; research has shown that the DDP-4 inhibitors helps stop
cancerous cells from spreading throughout the body. As a result, many
physicians and medical experts agree that the drug has the potential to
cause adverse conditions including thyroid and pancreatic cancers and
pancreatitis.
Plaintiffs File Januvia Lawsuits against Merck
Patients
who had been taking the medication and suffered serious side effects
allege that, although the FDA required Merck to complete specific
studies regarding the safety of the drug, the manufacturer delayed the
process, thus drastically reducing the possibility of finding side
effects or risks of serious health conditions before the drug was
marketed for sale to the public. Plaintiffs in Januvia lawsuits allege
that, had Merck acted according to the FDA’s direction, these health
risks would have been apparent much sooner, and patients would have been
informed of the effects and possibility of developing cancers before
the issue became more serious.
Physicians maintain that some side effects are relatively common from taking the medication including:
- Diarrhea
- Constipation
- Nausea
- Stomach pain
- Sinus complications
- Sore throat
However, many plaintiffs in Januvia lawsuits allege that they suffered from even more adverse effects including:
- Severe skin reaction as noted by painful sensation on the skin, sore throat, rashes, burning eyes, facial swelling and fever
- Gaining a rapid amount of weight quickly
- Shortness of breath
- Swelling of face or body
- Difficulty urinating or not urinating at all
Patients
who were eventually diagnosed with pancreatitis did not initially know
that they had the disease when they first started noticing symptoms;
rather, many plaintiffs in Januvia lawsuits allege that they were not
fully aware that these side effects were the start of the condition.
Most notably, patients claimed that they suffered from nausea, vomiting,
decreased or loss of interest in food, irregular or increased heart
rate and a severe pain that traveled from the stomach to the back.
Research Concludes Januvia May Cause Cancer
Researchers
conducted studies in both May 2009 and again in 2011 to examine the
possible connection between Januvia, pancreatitis and pancreatic cancer;
the results confirmed that although the drug has been successful in
helping people with type 2 diabetes manage their blood glucose levels,
there was indeed an increased risk of developing both health conditions
by taking the medication. The latter study reported participants taking
the drug had a six-fold probability of suffering from pancreatitis
further down the road, and those taking the drug had a two-fold
possibility of developing pancreatic cancer in the future.
Physicians
are warning consumers to conduct research before using the drug,
particularly because it took over three years for these results to
become apparent; there is no telling how long it may be before the
medication is linked to other serious health conditions.
FDA Requests a Revision to Label
The
FDA has acknowledged that they are currently investigating Januvia as
the result of its possible link to serious health conditions. In fact,
the FDA has reported evidence of inflammation and various levels of
pre-cancerous cell changes in sample tissues they obtained from patients
who were reportedly taking the medication.
However, in September
2009, the FDA requested that Merck revise the label on the medication to
acknowledge the new and potential hazardous side effects associated
with the drug. The FDA maintained that consumers must be warned prior to
the initial dose and be aware of the current reports of the potential
to develop various forms of acute pancreatitis. Additionally, the FDA
asked the manufacturer to ensure that physicians and healthcare
professionals knew to monitor their patients after prescribing the
medication or after the dosage was increased in order to watch for the
first signs of pancreatitis. Merck was also asked to instruct doctors to
cease prescribing the drug if their patients started to report serious
complications.
In the letter issued to Merck, the FDA maintained
that Merck should acknowledge that the drug only be used with thorough
monitoring methods, particularly in those who are at a predisposed risk
of developing pancreatic cancer and pancreatitis and especially in
patients who have a medical history of the diseases. Unfortunately, even
though the FDA requested Merck make the necessary changes to the label
and conduct further research in 2009, the organization still needed to
chastise the manufacturer for failing to follow through by 2012.
Contact Us
Have
you or a loved one been diagnosed with type 2 diabetes and been
prescribed Januvia to help monitor your blood glucose levels? If you are
currently taking the medication and are experiencing serious side
effects or have been diagnosed with pancreatic or thyroid cancer,
contact the American Injury Attorney Group. We will review your case, free of charge, and help to determine if you can file a claim against Merck to seek compensation.
- See more at: http://attorney-group.com/januvia-lawsuits/#sthash.ZNeECGKY.wqzr8gVr.dpuf
Januvia Lawsuits
What is Januvia?
Januvia (sitagliptin) was first approved in October 2006 by the U.S. Food and
Drug Administration (
FDA).
The drug was created in an effort to help patients previously diagnosed
with type 2 diabetes gain control of their blood glucose levels. The
first of its kind, the oral medication was classified as a DPP-4
inhibitor that helped to increase the body’s production of insulin.
Unfortunately, studies have shown that the drug may directly raise the
patient’s risk of developing pancreatitis and pancreatic cancer
following an initial dose and subsequent dosage increases. Patients
experiencing these side effects have filed Januvia lawsuits seeking
damages for their suffering.
History of Januvia
Januvia
was created by Merck & Co., Inc. to help the body produce insulin
by affecting the incretin system and targeting pancreatic cells, yet it
may also restrict the body from fighting against various types of
cancer; research has shown that the DDP-4 inhibitors helps stop
cancerous cells from spreading throughout the body. As a result, many
physicians and medical experts agree that the drug has the potential to
cause adverse conditions including thyroid and pancreatic cancers and
pancreatitis.
Plaintiffs File Januvia Lawsuits against Merck
Patients
who had been taking the medication and suffered serious side effects
allege that, although the FDA required Merck to complete specific
studies regarding the safety of the drug, the manufacturer delayed the
process, thus drastically reducing the possibility of finding side
effects or risks of serious health conditions before the drug was
marketed for sale to the public. Plaintiffs in Januvia lawsuits allege
that, had Merck acted according to the FDA’s direction, these health
risks would have been apparent much sooner, and patients would have been
informed of the effects and possibility of developing cancers before
the issue became more serious.
Physicians maintain that some side effects are relatively common from taking the medication including:
- Diarrhea
- Constipation
- Nausea
- Stomach pain
- Sinus complications
- Sore throat
However, many plaintiffs in Januvia lawsuits allege that they suffered from even more adverse effects including:
- Severe skin reaction as noted by painful sensation on the skin, sore throat, rashes, burning eyes, facial swelling and fever
- Gaining a rapid amount of weight quickly
- Shortness of breath
- Swelling of face or body
- Difficulty urinating or not urinating at all
Patients
who were eventually diagnosed with pancreatitis did not initially know
that they had the disease when they first started noticing symptoms;
rather, many plaintiffs in Januvia lawsuits allege that they were not
fully aware that these side effects were the start of the condition.
Most notably, patients claimed that they suffered from nausea, vomiting,
decreased or loss of interest in food, irregular or increased heart
rate and a severe pain that traveled from the stomach to the back.
Research Concludes Januvia May Cause Cancer
Researchers
conducted studies in both May 2009 and again in 2011 to examine the
possible connection between Januvia, pancreatitis and pancreatic cancer;
the results confirmed that although the drug has been successful in
helping people with type 2 diabetes manage their blood glucose levels,
there was indeed an increased risk of developing both health conditions
by taking the medication. The latter study reported participants taking
the drug had a six-fold probability of suffering from pancreatitis
further down the road, and those taking the drug had a two-fold
possibility of developing pancreatic cancer in the future.
Physicians
are warning consumers to conduct research before using the drug,
particularly because it took over three years for these results to
become apparent; there is no telling how long it may be before the
medication is linked to other serious health conditions.
FDA Requests a Revision to Label
The
FDA has acknowledged that they are currently investigating Januvia as
the result of its possible link to serious health conditions. In fact,
the FDA has reported evidence of inflammation and various levels of
pre-cancerous cell changes in sample tissues they obtained from patients
who were reportedly taking the medication.
However, in September
2009, the FDA requested that Merck revise the label on the medication to
acknowledge the new and potential hazardous side effects associated
with the drug. The FDA maintained that consumers must be warned prior to
the initial dose and be aware of the current reports of the potential
to develop various forms of acute pancreatitis. Additionally, the FDA
asked the manufacturer to ensure that physicians and healthcare
professionals knew to monitor their patients after prescribing the
medication or after the dosage was increased in order to watch for the
first signs of pancreatitis. Merck was also asked to instruct doctors to
cease prescribing the drug if their patients started to report serious
complications.
In the letter issued to Merck, the FDA maintained
that Merck should acknowledge that the drug only be used with thorough
monitoring methods, particularly in those who are at a predisposed risk
of developing pancreatic cancer and pancreatitis and especially in
patients who have a medical history of the diseases. Unfortunately, even
though the FDA requested Merck make the necessary changes to the label
and conduct further research in 2009, the organization still needed to
chastise the manufacturer for failing to follow through by 2012.
Contact Us
Have
you or a loved one been diagnosed with type 2 diabetes and been
prescribed Januvia to help monitor your blood glucose levels? If you are
currently taking the medication and are experiencing serious side
effects or have been diagnosed with pancreatic or thyroid cancer,
contact the American Injury Attorney Group. We will review your case, free of charge, and help to determine if you can file a claim against Merck to seek compensation.
- See more at: http://attorney-group.com/januvia-lawsuits/#sthash.ZNeECGKY.wqzr8gVr.dpuf
